New treatment strategies for severe sepsis and septic shock

Current Opinion in Critical Care

Volumn 9, Issue 5, 2003, Pages 390-396

  Patel, Gourang P ^a   Gurka, David P ^a   Balk, Robert A ^a  

^a RUSH MEDICAL COLLEGE   (United States)

Author keywords

Activated protein C; Antibiotics; Coagulation; Corticosteroids; Hyperglycemia; Sepsis; Septic shock; Vasopressors

Indexed keywords

ACTIVATED PROTEIN C; ANTIBIOTIC AGENT; CD14 ANTIGEN; COAGULATING AGENT; CORTICOSTEROID; CORTICOTROPIN; DROTRECOGIN; ERYTHROPOIETIN; FLUDROCORTISONE; HYDROCORTISONE; HYPERTENSIVE AGENT; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADRENAL FUNCTION; ANEMIA; ANTIBIOTIC THERAPY; ASSISTED VENTILATION; CAUSE OF DEATH; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; CRITICAL ILLNESS; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DNA POLYMORPHISM; DOUBLE BLIND PROCEDURE; DRUG APPROVAL; DRUG EFFICACY; DYSPNEA; ERYTHROCYTE TRANSFUSION; GASTROINTESTINAL HEMORRHAGE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HEALTH CARE COST; HEMODYNAMIC MONITORING; HOSPITAL INFECTION; HUMAN; HYPOTENSION; LABORATORY TEST; LOBAR PNEUMONIA; LUNG EDEMA; LUNG EMBOLISM; MAINTENANCE THERAPY; MEDICARE; META ANALYSIS; MORBIDITY; MORTALITY; MULTICENTER STUDY; MYOPATHY; NUTRITIONAL DEFICIENCY; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; POLYNEUROPATHY; PROMOTER REGION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REIMBURSEMENT; RESUSCITATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEPSIS; SEPTIC SHOCK; SURVIVAL; THROMBOCYTOPENIA; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT PLANNING;

ACUTE DISEASE; ADRENAL CORTEX HORMONES; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS; CRITICAL CARE; HUMANS; HYPERGLYCEMIA; INSULIN; NOREPINEPHRINE; PROGNOSIS; PROTEIN C; RECOMBINANT PROTEINS; SEPSIS; SHOCK, SEPTIC; SURVIVAL RATE; UNITED STATES; VASOCONSTRICTOR AGENTS; VENTILATORS, MECHANICAL;

EID: 0141562259     PISSN: 10705295     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075198-200310000-00009     Document Type: Review

References (61)

1. Bone RC, Balk RA, Cerra FB, et al.: Definition for sepsis and organ failure and guidelines for use of innovative therapies in sepsis: American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101:1644-1655.
2. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 2003, 342:138-150. Excellent and comprehensive review of the pathophysiology of the septic response and relates specific treatment alternatives to the pathogenesis.
3. Balk RA: Severe sepsis and septic shock: definitions, epidemiology, and clinical manifestations. Crit Care Clin 2000, 16:179-192.
4. Angus DC, Linde-Zwirble WT, Lidicker J, et al.: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310.
5. Martin GS, Mannino DM, Eaton S, et al.: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003, 348:1546-1554.
6. Dinarello CA: Anti-cytokine therapies in response to systemic infection. J Invest Derm Symposium Proc 2001, 6:244-250.
7. Tschaikowsky K, Hedwig-Geissing M, Schiele A, et al.: Coincidence of pro-and anti-inflammatory responses in the early phase of severe sepsis: longitudinal study of mononuclear histocompatibility leukocyte antigen-DR expression, procalcitonin, C-reactive protein, and changes in T-cell subsets in septic and postoperative patients. Crit Care Med 2002, 30:1015-1023.
8. Power C, Fanning N, Redmond HP: Cellular apoptosis and organ injury in sepsis: a review. Shock 2002, 18:197-211. Comprehensive review of the pathophysiological processes involved in sepsis and the development of organ dysfunction.
9. Landry DW, Oliver JA: The pathogenesis of vasodilatory shock. N Engl J Med 2001, 345:588-595.
10. Balk RA, Goyette RE: Multiple organ dysfunction syndrome in patients with severe sepsis: more than just inflammation. In Advances in the Diagnosis and Management of the Patient with Severe Sepsis. Edited by Balk RA. International Congress and Symposium Series 249. London: Royal Society of Medicine Press; 2002:39-60.
11. Schluter B, Raufhake C, Erren M, et al.: Effect of the interleukin-6 promoter polymorphism (-174 G/C) on the incidence and outcome of sepsis. Crit Care Med 2002, 30:32-37.
12. Ma P, Chen D, Pan J, et al.: Genomic polymorphism within interleukin-1 family cytokines influence the outcome of septic patients. Crit Care Med 2002, 30:1046-1050.
13. Gibot S, Cariou A, Drouet L, et al.: Association between a genomic polymorphism within the CD14 locus and septic shock susceptibility and mortality rate. Crit Care Med 2002, 30:969-973.
14. Mira JP, Cariou A, Grall F, et al.: Association of TNF2, a TNF-α promoter polymorphism, with septic shock susceptibility and mortality. JAMA 1999, 282:561-568.
15. Tang GJ, Huang SL, Yien HW, et al.: Tumor necrosis factor gene polymorphism and septic shock in surgical infection. Crit Care Med 2000, 28:2733-2736.
16. Lorenz E, Mira JP, Frees KL, et al.: Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch Intern Med 2002, 162:1028-1032. Interesting presentation of patients who have an increased of for gram-negative sepsis related to changes in their genetic makeup for the lipopolysaccharide receptor on the mononuclear cell wall. Presents implications for possible treatment.
17. Wheeler AP, Bernard GR: Treating patients with severe sepsis. N Engl J Med 1999, 340:207-214.
18. Annane D, Sebille V, Charpeutier C, et al. Effect of treatment with low doses of hydrocortisone and fludricortisone on mortality in patients with septic shock. JAMA 2002, 288:862-871. The article that has reinvigorated supporters of the use of steroids for the treatment of severe sepsis and septic shock. Defines a group of patients with severe septic shock who might benefit from more physiologic doses of steroid replacement.
19. Rivers E, Nguyen B, Havstad S, et al.: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001, 345:1368-1377.
20. Van den Berghe G, Wouters PJ, Weekers F, et al.: Intensive insulin therapy in critically ill patients. N Engl J Med 2001, 345:1359-1367.
21. Bernard GR, Vincent JL, Laterre P, et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709.
22. Simon D, Trenholme G: Antibiotic selection for patients with septic shock. Crit Care Clin 2000, 16:215-231.
23. Dellinger RP: Cardiovascular management of septic shock. Crit Care Med 2003, 31:946-955. Comprehensive discussion of the cardiovascular and hemodynamic derangements in patients with severe sepsis.
24. Martin C, Viviand X, Leone M, et al.: Effect of norepinephrine on the outcome of septic shock. Crit Care Med 2000, 28:2758-2765.
25. Holmes CL, Patel BM, Russell JA, et al.: Physiology of vasopressin relevant to management of septic shock. Chest 2001, 120:989-1002.
26. Sharshar T, Carlier R, Blanchard A, et al.: Depletion of neurohypophyseal content of vasopressin in septic shock. Crit Care Med 2002, 30:497-500. Presents the rationale for the use of vasopressin in the management of patients with septic shock.
27. Stewart TE: Controversies around lung protective mechanical ventilation. Am J Respir Crit Care Med 2002, 166:1421-1422.
28. Pinhu L, Whitehead T, Evans T, et al.: Ventilator associated lung injury. Lancet 2003, 361:332-340. Excellent review of the complex pathophysiological processes involved in the production of ventilator-associated lung injury.
29. The Acute Respiratory Distress Syndrome Network: Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000, 342:1301-1308.
30. Eichacker PQ, Gerstenberger EP, Banks SM, et al.: Meta-analysis of acute lung injury and acute respiratory distress syndrome trials testing low tidal volumes. Am J Respir Crit Care Med 2002, 166:1510-1514. Controversial and thought-provoking review of the clinical trials evaluating low tidal volume ventilatory support in the management of patients with acute lung injury. Suggests that the end-inspiratory plateau pressure is more important in the pathogenesis of injury than is the tidal volume.
31. Chen P: Vasopresssin: new uses in critical care. Am J Med Sci 2002, 324:146-154.
32. Patel BM, Chittock DR, Russell JA, et al.: Beneficial effects of short-term vasopressin infusion during severe septic shock. Anethesiology 2002, 96:576-582.
33. Van den Berghe G, Wouters PJ, Boruillon R, et al.: Outcome benefit of intensive insulin therapy in critically ill: insulin dose versus glycemic control. Crit Care Med 2003, 31:359-366. Demonstrates that control of blood glucose is more important than the administration of insulin.
34. Marik PR, Zaloga GP: Adrenal insufficiency in the critically ill. Chest 2002, 122:1784-1796. Excellent review of the hypothalamic-pituitary-adrenal axis and how to evaluate adrenal function in the critically ill patient.
35. Cooper MS, Stewart PM: Corticosteroid insufficiency in acutely ill patients. N Engl J Med 2003, 348:727-734. Good review of the importance of multiple factors on hypothalamic-pituitary-adrenal axis function and evaluation in the critically ill patient.
36. Balk RA: Steroids for septic shock: back from the dead? (Pro) Chest 2003; 123:490S-499S.
37. Sessler CN: Steroids for septic shock: back from the dead? (Con) Chest 2003; 123:482S-489S.
38. Balk RA: Pathogenesis and management of multiple organ dysfunction or failure in severe sepsis and septic shock. Crit Care Clin 2000, 16:337-352.
39. Akca S, Haji-Michael P, de Mendonca A, et al.: Time course of platelet counts in critically ill patients. Crit Care Med 2002, 30:753-756. Describes the time course of a common clinical finding in the critically ill patient.
40. Rodriguez RM, Corwin HL, Gettinger A, et al.: Nutritional deficiencies and blunted erythropoietin response as causes of the anemia of critical illness. J Crit Care 2001, 16:36-41.
41. Taylor RW, Manganaro L, O'Brien J, et al.: Impact of allogenic packed red blood cell transfusion on nosocomial infection rates in critically ill patient. Crit Care Med 2002, 30:2249-2254. Highlights an association of increased infection rates and mortality in those critically ill patients who receive packed erythrocyte transfusions.
42. Kopko PM, Marshall CS, Mackenzie MR: Transfusion-related acute lung injury. JAMA 2002, 287:1968-1971.
43. Aiboshi J, Moore EE, Ciesla DJ, et al.: Blood transfusion and the two-insult model of post-injury multiple organ failure. Shock 2001, 12:302-306.
44. Corwin HL, Gettinger A, Pearl R, et al.: Efficacy of recombinant human erythropoietin in critically ill patients. JAMA 2002, 288:2827-2835.
45. Graf J, Doig GS, Cook DJ, et al.: Randomized, controlled clinical trials in sepsis: has methodological quality improved over time? Crit Care Med 2002, 20:461-472.
46. Eichacker PQ, Parent C, Kalil A, et al.: Risk and the efficacy of antiinflammatory agents: Restrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 2002, 166:1197-1205. Interesting discussion concerning the lack of correlation between the preclinical experimental data and the results of clinical trials in the management of sepsis.
47. Taylor FB Jr, Peer GT, Lockhart MS, et al.: Endothelial cell protein C receptor plays an important role in protein C activation in vivo. Blood 2001, 97:1685-1688.
48. Siegel JP: Assessing the use of activated protein C in the treatment of severe sepsis. N Engl J Med 2002, 347:1030-1034.
49. Warren HS, Suffredini AF, Eichacker PQ, et al.: Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med 2002, 347:1027-1030.
50. Ely EW, Laterre PF, Angus DC, et al.: Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003, 31:12-19. Details the response of various clinical groups of sepsis patients in relationship to their response to APC treatment from the PROWESS trial.
51. Angus DC, Linde-Zwirble WT, Clermont G, et al.: Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med 2003, 31:1-11. Cost-effectiveness data of APC compared to other established treatments and preventive measures.
52. Vincent JL, Angus DC, Artigas A, et al.: Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 2003, 31:834-840. Reviews the effect of APC on organ system function and recovery from dysfunction.
53. Eichacker PQ, Natanson C: Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials. Crit Care Med 2003, 31:S94-S96.
54. Bernard GR: Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis. Crit Care Med 2003, 31:S85-S93.
55. Manns BJ, Lee H, Doig J, et al.: An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med 2002, 347:993-1000. A Canadian perspective on the economic impact and cost-effectiveness of APC.
56. Medicare Program: Changes to the hospital inpatient prospective payment systems and fiscal year 2003 rates. Final rule. Fed Regist 2002, 67:49981-50289.
57. Teres D, Rapoport J, Lemeshow S, et al.: Effects of severity of illness on resource use by survivors and nonsurvivors of severe sepsis at intensive care unit admission. Crit Care Med 2002, 30:2413-2419.
58. Calvano SE, Coyle SM, Barbosa KS, et al.: Multivariate analysis of 9 disease-associated variables for outcome prediction in patients with sepsis. Arch Surg 1998, 133:1347-1350.
59. Heyland DK, Hopman W, Coo H, et al.: Long-term health-related quality of life in survivors of sepsis. Short form 36: a valid and reliable measure of health-related quality of life. Crit Care Med 2000, 28:2599-2605.
60. Brun-Buisson C, Doyon F, Carlet J, et al.: Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. JAMA 1995, 274:968-974.
61. Jimenez MF, Marshall JC: Source control in the management of sepsis. Intensive Care Med 2001, 27:S49-S62.